GC Cell Corporation (KOSDAQ: A144510)
Health Care · Biotechnology · KR
₩13,720.00
-6.03% today · -28.2% 1Y
GC Cell Corporation (KOSDAQ: A144510) operates in the Biotechnology industry within the Health Care sector. The company is valued at $148.77M.
Over the last twelve months the share price has lost 28.2%, trading between 11.61K and 28.45K.
Tweenvest scores GC Cell Corporation across four factors: quality 45/100, value 56/100. Its strongest factor is value.
A144510 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $148.77M
- Revenue (TTM)
- $107.31M
- P/E
- —
- EPS
- -17,167.74
- Dividend yield
- —
- Beta (5Y)
- 0.57
- 52-week high
- ₩28,450.00
- 52-week low
- ₩11,610.00
- Avg volume (3M)
- —
- Shares outstanding
- 15.03M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.07 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.98 | +0.26% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.96 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $549.00 | +0.26% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $834.94 | +0.78% |
| argenx SEENXTBR: ARGX | $63.06B | €872.80 | +1.00% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.62 | +1.97% |
Figures last refreshed Aug 18, 2026.